CN1662222A - 包含α-硫辛酸(衍生物)的自由流动的粉状组合物 - Google Patents
包含α-硫辛酸(衍生物)的自由流动的粉状组合物 Download PDFInfo
- Publication number
- CN1662222A CN1662222A CN038139669A CN03813966A CN1662222A CN 1662222 A CN1662222 A CN 1662222A CN 038139669 A CN038139669 A CN 038139669A CN 03813966 A CN03813966 A CN 03813966A CN 1662222 A CN1662222 A CN 1662222A
- Authority
- CN
- China
- Prior art keywords
- acid
- compositions
- alpha
- flow
- flow promortor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 13
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 235000005911 diet Nutrition 0.000 claims abstract description 4
- 239000008247 solid mixture Substances 0.000 claims abstract description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 72
- 235000019136 lipoic acid Nutrition 0.000 claims description 71
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 17
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 230000006835 compression Effects 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 229960003624 creatine Drugs 0.000 claims description 4
- 239000006046 creatine Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 3
- -1 creatine dihydrolipoic acid salt Chemical class 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000598 lipoate effect Effects 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- UUDFBRWLHZIIQX-UHFFFAOYSA-M sodium;5-(dithiolan-3-yl)pentanoate Chemical compound [Na+].[O-]C(=O)CCCCC1CCSS1 UUDFBRWLHZIIQX-UHFFFAOYSA-M 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 3
- 230000000378 dietary effect Effects 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 125000005624 silicic acid group Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000004744 fabric Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000005245 sintering Methods 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001795 light effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- NBMATVIMURBZTQ-UHFFFAOYSA-N 5-(trithian-4-yl)pentanoic acid Chemical compound OC(=O)CCCCC1CCSSS1 NBMATVIMURBZTQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Detergent Compositions (AREA)
Abstract
Description
容器No. | 孔口宽度[mm] | 当粉末刚刚仍能连续流过时的评定 |
1 | 2.5 | 非常良好 |
2 | 5 | 良好 |
3 | 8 | 总体良好 |
4 | 12 | 刚刚满足要求 |
5 | 18 | 有缺陷 |
6 | 不满足要求(粉末不流过No.5) |
锥形堆高度[mm] | 评定 | 得分 |
<20 | 非常良好 | 1 |
21-30 | 良好 | 2 |
31-40 | 刚刚满足要求 | 3 |
41-50 | 有缺陷 | 4 |
>50 | 不满足要求 | 5 |
得分 | 行为特性 |
1=非常良好 | 完全未变化和通过孔口容器No.2顺利流动(表1) |
2=良好 | 部分疏松粘合,容易崩解成初始状态 |
3=总体良好 | 疏松成形;在轻微手指压力下基本上崩解成粉末 |
4=刚刚满足要求 | 疏松结块;采用手指测试仍然崩解成最细小的颗粒 |
5=有缺陷 | 半固体结块;采用手指测试不再崩解成最细小的颗粒 |
6=不满足要求 | 坚硬成形 |
# | 流动助剂 | 重量比例 | 流动得分 | 锥形堆高度[mm] | 耐压力性 |
1 | n/a | n/a | 4 | 30 | 4-5 |
2 | n/a | n/a | 6 | 不可测量,锥体脱落 | 6 |
3 | Sipernat320 | 1.0 | 5 | 不可测量,锥体脱落 | 5-6 |
4 | 1.5 | 5 | 5-6 | ||
5 | 2.0 | 4 | 29 | 5 | |
6 | Sipernat22S | 1.0 | 2 | 25 | 6 |
7 | 1.5 | 2 | 22 | 5-6 | |
8 | 2.0 | 2 | 21 | 5 | |
9 | 3.0 | 2 | 20 | 4-5 | |
10 | Sipernat50S | 1.0 | 2 | 23 | 5 |
11 | 1.5 | 2 | 21 | 4-5 | |
12 | 2.0 | 2 | 19 | 4 | |
13 | 3.0 | 2 | 19 | 4 | |
14 | Sipernat500LS | 1.0 | 2 | 22 | 4-5 |
15 | 1.5 | 2 | 19 | 4 | |
16 | 2.0 | 2 | 19 | 3-4 | |
17 | 3.0 | 2 | 20 | 3- | |
18 | SiloxTM2 | 1.5 | 4 | n/a | 4-5 |
19 | 2.0 | 3 | n/a | 3-4 |
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10223882.0 | 2002-05-29 | ||
DE10223882A DE10223882A1 (de) | 2002-05-29 | 2002-05-29 | Fliessfähige, pulverförmige Liponsäure(-Derivate) enthaltende Zusammensetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1662222A true CN1662222A (zh) | 2005-08-31 |
CN100335037C CN100335037C (zh) | 2007-09-05 |
Family
ID=29557379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038139669A Expired - Fee Related CN100335037C (zh) | 2002-05-29 | 2003-05-28 | 包含α-硫辛酸(衍生物)的自由流动的粉状组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7993676B2 (zh) |
EP (1) | EP1507515B1 (zh) |
JP (1) | JP4891543B2 (zh) |
CN (1) | CN100335037C (zh) |
AT (1) | ATE503464T1 (zh) |
DE (2) | DE10223882A1 (zh) |
ES (1) | ES2359697T3 (zh) |
HK (1) | HK1070833A1 (zh) |
WO (1) | WO2003099256A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4556061B2 (ja) * | 2006-07-27 | 2010-10-06 | ビーエイチエヌ株式会社 | ヒアルロン酸産生増強剤 |
DE102007034102A1 (de) * | 2007-07-21 | 2009-01-22 | Alzchem Trostberg Gmbh | Abriebfeste und rieselfähige Glycocyamin-haltige Formlinge und Verfahren zu deren Herstellung |
DE102007038849A1 (de) | 2007-08-16 | 2009-02-19 | Adscil Gmbh | Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie |
JP5245061B2 (ja) * | 2010-05-12 | 2013-07-24 | ビーエイチエヌ株式会社 | 経口用老化防止剤及び美容方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2871154A (en) * | 1955-10-11 | 1959-01-27 | Du Pont | Fungicidal compositions and methods employing lipoic acids |
DE3409063A1 (de) * | 1984-03-13 | 1985-09-19 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von fliessfaehigen cholinchlorid-kieselsaeure-pulvern |
US4623478A (en) * | 1984-06-22 | 1986-11-18 | U.S. Peroxygen Company | Composition and method for making foamed polyester resin |
DK0427247T3 (da) | 1989-11-09 | 1998-09-28 | Asta Medica Ag | Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel |
DE4218572A1 (de) | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
DE4218768A1 (de) * | 1992-06-06 | 1993-12-09 | Basf Ag | Verfahren zur Herstellung von Cholinchlorid enthaltenden Pulvern, diese Pulver und ihre Verwendung |
DE4235912C2 (de) * | 1992-10-23 | 2002-12-05 | Viatris Gmbh | Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung |
US5691294A (en) * | 1993-03-30 | 1997-11-25 | The Procter & Gamble Company | Flow aids for detergent powders comprising sodium aluminosilicate and hydrophobic silica |
DE19705555A1 (de) * | 1997-02-13 | 1998-08-20 | Ulrich Dr Posanski | Pharmazeutische Präparate der Thioctsäure zur oralen Anwendung |
DE19938098A1 (de) * | 1999-08-12 | 2001-02-15 | Woerwag Pharma Gmbh & Co | Feste Arzneimittelformulierung mit hohem Gehalt an Thioctsäure (alpha-Liponsäure) |
US6387945B2 (en) * | 2000-04-11 | 2002-05-14 | The Regents Of The University Of California | Lipoic acid analogs |
DE10105750A1 (de) * | 2001-02-08 | 2002-10-10 | Degussa | Fällungskieselsäuren mit enger Partikelgrößenverteilung |
EP1290997A1 (en) * | 2001-09-05 | 2003-03-12 | Degussa AG | Homogeneous microfilled dental composite material and method of preparation |
-
2002
- 2002-05-29 DE DE10223882A patent/DE10223882A1/de not_active Withdrawn
-
2003
- 2003-05-28 CN CNB038139669A patent/CN100335037C/zh not_active Expired - Fee Related
- 2003-05-28 ES ES03732496T patent/ES2359697T3/es not_active Expired - Lifetime
- 2003-05-28 JP JP2004506781A patent/JP4891543B2/ja not_active Expired - Lifetime
- 2003-05-28 DE DE50313582T patent/DE50313582D1/de not_active Expired - Lifetime
- 2003-05-28 WO PCT/EP2003/005663 patent/WO2003099256A2/de active Application Filing
- 2003-05-28 AT AT03732496T patent/ATE503464T1/de active
- 2003-05-28 US US10/515,671 patent/US7993676B2/en not_active Expired - Fee Related
- 2003-05-28 EP EP03732496A patent/EP1507515B1/de not_active Expired - Lifetime
-
2005
- 2005-04-29 HK HK05103681.3A patent/HK1070833A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1070833A1 (en) | 2005-06-30 |
WO2003099256A2 (de) | 2003-12-04 |
CN100335037C (zh) | 2007-09-05 |
WO2003099256A3 (de) | 2004-04-01 |
US7993676B2 (en) | 2011-08-09 |
US20050220884A1 (en) | 2005-10-06 |
ES2359697T3 (es) | 2011-05-26 |
EP1507515A2 (de) | 2005-02-23 |
DE10223882A1 (de) | 2003-12-18 |
DE50313582D1 (de) | 2011-05-12 |
EP1507515B1 (de) | 2011-03-30 |
JP4891543B2 (ja) | 2012-03-07 |
ATE503464T1 (de) | 2011-04-15 |
JP2005532329A (ja) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1195498C (zh) | 直接压制的固态剂量制剂 | |
EP3174530B1 (de) | Direkt verpressbare polyvinylalkohole | |
WO2008101943A1 (en) | Pharmaceutical metformin hydrochloride formulation and tablet comprising said formulation | |
KR20120016075A (ko) | 만니톨과 과립형 전분의 압축성 및 유동성 공응집체 | |
CN100335037C (zh) | 包含α-硫辛酸(衍生物)的自由流动的粉状组合物 | |
JPH03133922A (ja) | 活性化合物の徐放性を示す圧縮成形物品 | |
EP3362054B1 (en) | Pregabalin compositions | |
CN1279899C (zh) | 含支链氨基酸颗粒的生产方法 | |
CN1232252C (zh) | 包含α-硫辛酸(衍生物)的延时释放剂型 | |
JP2007063217A (ja) | プランルカスト水和物含有錠及びその製造方法 | |
WO2022004871A1 (ja) | 錠剤およびその製造方法 | |
EP2671569B1 (en) | Stable pharmaceutical compositions with fast onset | |
JPWO2018159673A1 (ja) | エリスリトール顆粒およびその製造方法、ならびにそれを用いた錠剤の製造方法および錠剤 | |
JP2008162966A (ja) | プランルカスト水和物の付着凝集性を低減する方法 | |
JP4402350B2 (ja) | 固形医薬品組成物およびその製造方法 | |
CN1889934A (zh) | 含加巴喷丁的药物制品 | |
CN107569473A (zh) | 一种盐酸氨溴索缓释胶囊及其制备方法 | |
JP2005532329A5 (zh) | ||
EP3487484B1 (de) | Atorvastatin-zusammensetzung | |
WO2023145119A1 (ja) | ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤 | |
CN101778631B (zh) | 医药片剂的制造方法 | |
WO2023145867A1 (ja) | 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤 | |
EP2922907A1 (en) | Process for preparing a granulated product from a powder composition | |
JPH03178927A (ja) | 有効物質を遅れずに放出する圧縮物、その製造方法およびかゝる圧縮物を製造する為にポリヒドロキシ酪酸を用いる方法 | |
CN117860681A (zh) | 一种头孢噻肟钠粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: EVONIK DEGUSSA GMBH Free format text: FORMER OWNER: DEGUSSA Effective date: 20080926 Owner name: AOZE CHEMICAL TELUOSITE BEIGE CO.LTD. Free format text: FORMER OWNER: EVONIK DEGUSSA GMBH Effective date: 20080926 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080926 Address after: German Trost Begg Patentee after: Ozer Chemical Trostberg GmbH Address before: essen Patentee before: Evonik Degussa GmbH Effective date of registration: 20080926 Address after: essen Patentee after: EVONIK DEGUSSA GmbH Address before: German Trost Begg Patentee before: Degussa AG |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140820 Address after: German Trost Begg Patentee after: Aozer Chemical Co.,Ltd. Address before: German Trost Begg Patentee before: Alzchem Trostberg GmbH |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070905 Termination date: 20150528 |
|
EXPY | Termination of patent right or utility model |